Mochida announces License Agreement with Merck

Mochida announces License Agreement with Merck
Mochida Pharmaceutical Co., Ltd.
(Tokyo, December 13, 2011) Mochida Pharmaceutical Co., Ltd. announces that it has entered into a License Agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, relating to a portfolio of drug candidates invented by Mochida for the potential treatment for type-2 diabetes. Under the terms of the agreement, Merck has been granted a worldwide exclusive license to develop, manufacture, use and sell the potential drug candidates. Mochida will receive from Merck an upfront payment and potential development milestone payments, as well as royalties on the sales of any products derived from the collaboration. Mochida has retained an option to co-develop and co-market any products in Japan.
Focusing on the fields of chronic pain, diabetes and obesity, Mochida Discovery Research has been promoting innovative research for novel pharmaceutical candidates that can be introduced into global market, and also has been actively collaborating with external research facilities as well as licensing both in Japan and overseas. Mochida will continue to actively seek opportunities of in- and out-licenses, and pursue alliances with potential partners.
This agreement will have only minor impact on the business performance of Mochida for the near term.
Contacts for inquiries:
Public Relations, Mochida Pharmaceutical Co., Ltd.
E-mail [email protected]

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.